Randomized Controlled Trials on Chinese Herbal Medicine Therapy for Atopic Dermatitis： An Evidence Map
10.13422/j.cnki.syfjx.20251723
- VernacularTitle:中药治疗特应性皮炎的临床研究证据图分析
- Author:
Mingyue LIU
1
;
Baixiang HE
2
;
Jingqiu HU
3
;
Youran DAI
4
;
Lingling REN
5
;
Shufan GE
6
;
Kelin LI
2
;
Qiubai JIN
7
;
Ping SONG
7
;
Huiyan CHI
7
Author Information
1. Graduate School， Beijing University of Chinese Medicine， Beijing 100029， China
2. Dongzhimen Hospital， Beijing University of Chinese Medicine， Beijing 100700， China
3. Yanbian University， Yanji 133000， China
4. Shijitan Hospital， Capital Medical University， Beijing 100038， China
5. Shandong University of Traditional Chinese Medicine， Jinan 250399， China
6. The First Affiliated Hospital of Anhui University of Chinese Medicine， Hefei 230038， China
7. Xiyuan Hospital， China Academy of Chinese Medical Sciences， Beijing 100091， China
- Publication Type:Journal Article
- Keywords:
Chinese herbal medicine;
atopic dermatitis;
evidence mapping;
randomized controlled trial;
evidence-based research
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2025;31(21):138-145
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo characterize the evidence distribution and methodological quality of randomized controlled trials （RCTs） on oral Chinese herbal medicine （CHM） for atopic dermatitis （AD） based on evidence mapping. MethodsSeven databases （CNKI， Wanfang Data， VIP， CBM， Cochrane Library， PubMed， and Embase） and the Chinese Clinical Trial Registry were searched for the RCTs in Chinese and English. Evidence distribution was presented graphically and textually， and methodological quality was assessed via the Cochrane Risk of Bias tool （ROB 1.0）. ResultsA total of 168 RCTs were included. The number of annual publications showing an increasing trend， and 72.6% RCTs had sample sizes of 51-100 participants. The studies evaluated 108 distinct CHM interventions categorized as decoctions， granules， Chinese patent medicines， and extracts. Compound Glycyrrhizin was the most frequently used， followed by Xiaofengsan and Chushi Weiling decoction. Among the RCTs， 57.1% had the treatment courses of 4-8 weeks. Outcome measures predominantly focused on clinical response rate， skin lesion severity scores， and adverse events， with less attention to TCM symptom scores， skin barrier function， and relapse rates. The overall risk of bias was generally high. ConclusionWhile CHM for AD is a research hotspot and demonstrates clinical advantages， the related studies have problems such as unclear clinical positioning， poor research standardization and methodological quality， and insufficient prominence of TCM clinical advantages. Large-sample， methodologically rigorous， and high-quality studies are needed to enhance the evidence base for CHM in treating AD.
